Metabolic Steatotic Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions
Editat de Mindie Nguyen, Linda Henryen Limba Engleză Paperback – 24 iun 2024
This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.
- Compiles the latest, up-to-date science from key experts in the field on metabolic fatty liver disease
- Reviews best practices and current guidelines for a comprehensive overview
- Identifies recommendations for future research endeavors
Preț: 781.92 lei
Preț vechi: 1023.51 lei
-24% Nou
Puncte Express: 1173
Preț estimativ în valută:
149.69€ • 155.60$ • 124.11£
149.69€ • 155.60$ • 124.11£
Carte tipărită la comandă
Livrare economică 29 ianuarie-12 februarie 25
Livrare express 31 decembrie 24 - 04 ianuarie 25 pentru 96.80 lei
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780323996495
ISBN-10: 0323996493
Pagini: 338
Dimensiuni: 191 x 235 x 19 mm
Greutate: 0.7 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0323996493
Pagini: 338
Dimensiuni: 191 x 235 x 19 mm
Greutate: 0.7 kg
Editura: ELSEVIER SCIENCE
Public țintă
Translational and clinical science researchers in digestive medicine; gastroenterologists and hepatologistsBariatric surgeons, transplant surgeons, nutritionists, endocrinologists, cardiologists, public and health policy makers
Cuprins
1. Global Epidemiology of NAFLD (now and forecasted)
2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA
3. Economic and patient reported outcome burden (now and forecasted)
4. NAFLD pathogenesis (environmental and genetic)
5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)
7. Screening, diagnosis, and evaluation of patients with NALFD
8. Non-invasive evaluation of liver fibrosis (serum-based)
9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)
10. General treatment principles
11. Non-surgical treatment of obesity and metabolic disease
12. Endoscopic and surgical treatment of obesity
13. Pharmacologic treatment of hepatic steatosis
14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies
15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases
16. Special populations: Fatty liver disease in patients with chronic hepatitis
2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA
3. Economic and patient reported outcome burden (now and forecasted)
4. NAFLD pathogenesis (environmental and genetic)
5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)
7. Screening, diagnosis, and evaluation of patients with NALFD
8. Non-invasive evaluation of liver fibrosis (serum-based)
9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)
10. General treatment principles
11. Non-surgical treatment of obesity and metabolic disease
12. Endoscopic and surgical treatment of obesity
13. Pharmacologic treatment of hepatic steatosis
14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies
15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases
16. Special populations: Fatty liver disease in patients with chronic hepatitis